nach oben

Current Dermatology Reports

Erschienen in:

18.06.2022 | Hot Topic

Human Skin Cancer: an Overview Of Animal, Ex Vivo, and In Vitro Models

verfasst von: Catalina Gaviria Agudelo, Luz Marina Restrepo

Erschienen in: Current Dermatology Reports | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Skin cancer is the most prevalent human cancer and has presented a considerable world incidence rate increase over the last years. While animals offer highly complex systems to study skin cancer biology, ethical concerns and the differences found between the human and animal skin have promoted the development of alternative methods. In this review, we provide an overview of the most important skin cancer models and describe the advantages of in vitro substitutes over ex vivo and animal models. To facilitate understanding, an insight into the biology of skin cancer is also given.

Recent Findings

Currently, the study of cancer pathology and the development of therapeutic agents are mostly based on animal experiments. The methodologies used are based on mice genetic modifications and the induction of carcinogenesis by UV radiation, chemicals, or viruses. Skin explant models represent one alternative to animal models. These preserve the structure and composition of native skin and are therefore highly suitable. More recent studies have developed in vitro skin models composed of the epidermal and/or the dermal layers, which more faithfully mimic the human skin.

Summary

Various technologies have been studied to create improved skin substitutes. To better understand skin cancer biology, models that more faithfully mimic the human skin are needed. In vitro systems can recreate many of the typical features of both healthy and diseased skin and suggest that complex systems like full-thickness models are highly valuable tools to perform human skin studies.

Bergers LIJC, et al. Immune-competent human skin disease models. Drug Discov Today. 2016;21(9):1479–88. https://doi.org/10.1016/j.drudis.2016.05.008.CrossRefPubMed

WebMD. “Skin cancer”. 2022. https://www.webmd.com/melanoma-skin-cancer/guide/skin-cancer#1-1. Accessed 7 Apr 2022.

Mahmudur M. “Characterisation of a novel in vitro model of Basal cell carcinoma (BCC) through stable PTCH1 suppression in immortalised human keratinocytes,” Queen Mary Unoversity of London, 2013.

World Health Organization. “Radiation: Ultraviolet (UV) radiation and skin cancer,” 2017. https://www.who.int/news-room/q-a-detail/radiation-ultraviolet-(uv)-radiation-and-skin-cancer. Accessed 7 Aug 2021.

Odashiro AN, Pereira PR, Marshall JC, Godeiro K, Burnier MN. Skin cancer models. Drug Discov Today Dis Model. 2005;2(1):71–5. https://doi.org/10.1016/j.ddmod.2005.05.011.CrossRef

Neagu M, et al. Chemically induced skin carcinogenesis: updates in experimental models (Review). Oncol Rep. 2016;35(5):2516–28. https://doi.org/10.3892/or.2016.4683.CrossRefPubMedPubMedCentral

Hill DS, Robinson NDP, Caley MP, Chen M, Toole EAO, Jane L. A novel fully-humanised 3D skin equivalent to model early melanoma invasion. Mol Cancer Ther. 2016;14(11):2665–73. https://doi.org/10.1158/1535-7163.MCT-15-0394.A.CrossRef

Skin Cancer Foundation. “Melanoma overview,” 2022. https://www.skincancer.org/skin-cancer-information/melanoma. Accessed 7 Apr 2022.

Skin Cancer Foundation. “Skin cancer facts & statistics,” 2022. https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/. Accessed 30 Feb 2021.

10.

Gober MD, Bashir HM, Seykora JT. Reconstructing skin cancers using animal models. Cancer Metastasis Rev. 2013;32(1–2):123–8. https://doi.org/10.1007/s10555-012-9410-8.CrossRefPubMedPubMedCentral

11.

Caulin C, et al. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest. 2007;117(7):1893–901. https://doi.org/10.1172/JCI31721.CrossRefPubMedPubMedCentral

12.

Canadian Cancer Society. “What is non-melanoma skin cancer?” 2018. http://www.cancer.ca/en/cancer-information/cancer-type/skin-non-melanoma/non-melanoma-skin-cancer/?region=on. Accessed 7 Apr 2018.

13.

Samarasinghe V, Madan V. Nonmelanoma skin cancer. J Cutan Aesthet Surg. 2012;5(1):3–10. https://doi.org/10.4103/0974-2077.94323.CrossRefPubMedPubMedCentral

14.

Wu X, Elkin EE, Marghoob AA. Burden of basal cell carcinoma in USA. Futur Oncol. 2015;11(22):2967–74. https://doi.org/10.2217/FON.15.180.CrossRef

15.

Noonan FP, et al. Neonatal sunburn and melanoma in mice. Nature. 2001;413(6853):271–2. https://doi.org/10.1038/35095108.CrossRefPubMed

16.

Huang P, Balmain A. “Modeling cutaneous squamous carcinoma development in the mouse,” Cold Spring Harb Perspect Med. 2014;1–24. https://doi.org/10.1101/cshperspect.a013623

17.

Huang M-T, et al. Inhibitory effect of topical applications of nondenatured soymilk on the formation and growth of UVB-induced skin tumors. Oncol Res. 2004;14(7–8):387–97. https://doi.org/10.3727/0965040041292350.CrossRefPubMed

18.

Aszterbaum M, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med. 1999;5(11):1285–91. https://doi.org/10.1038/15242.CrossRefPubMed

19.

Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997;276(5313):817–21. https://doi.org/10.1126/science.276.5313.817.CrossRefPubMed

20.

Xie J, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2. https://doi.org/10.1038/34201.CrossRefPubMed

21.

Nilsson M, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci. 2000;97(7):3438–43. https://doi.org/10.1073/pnas.050467397.CrossRefPubMedPubMedCentral

22.

Grachtchouk M, et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet. 2000;24(3):216–7. https://doi.org/10.1038/73417.CrossRefPubMed

23.

Nicolas M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416–21. https://doi.org/10.1038/ng1099.CrossRefPubMed

24.

Hochberg M. “Experimental models for BCC,” J Dermatology Clin Res. 2013;1(1).

25.

Carlson JA, Combates NJ, Stenn KS, Prouty SM. Anaplastic neoplasms arising from basal cellcarcinoma xenotransplants into SCID-beige mice. J Cutan Pathol. 2002;29(5):268–78. https://doi.org/10.1034/j.1600-0560.2002.290502.x.CrossRefPubMed

26.

Genoskin. “Ready-to-use ex vivo human skin models for cosmetic testing ,” 2018. https://www.genoskin.com/skin-models-cosmetic-testing/. Accessed 12 Dec 2019.

27.

Abd E, et al. “Skin models for the testing of transdermal drugs,” Clinical Pharmacology: Advances and Applications, vol. 8. Dove Medical Press Ltd. 2016;163–176. https://doi.org/10.2147/CPAA.S64788.

28.

Groeber F, Holeiter M, Hampel M, Hinderer S, Schenke-Layland K. Skin tissue engineering – in vivo and in vitro applications. Adv Drug Deliv Rev. 2011;63(4–5):352–66. https://doi.org/10.1016/j.addr.2011.01.005.CrossRefPubMed

29.

Poumay Y, Coquette A. Modelling the human epidermis in vitro: tools for basic and applied research. Arch Dermatol Res. 2007;298(8):361–9. https://doi.org/10.1007/s00403-006-0709-6.CrossRefPubMed

30.

Garlick JA. “Engineering skin to study human disease--tissue models for cancer biology and wound repair.,” Adv Biochem Eng Biotechnol. 2007;03(207–239). https://doi.org/10.1007/b137206.

31.

Genoskin. “Genoskin presents new skin cancer model at Meet2Win,” 2015. https://www.genoskin.com/en/tissue-samples/skin-cancer-model-oncoskin/. Accessed 7 Apr 2022.

32.

Eves P, et al. Characterization of an in vitro model of human melanoma invasion based on reconstructed human skin. Br J Dermatol. 2000;142(2):210–22. https://doi.org/10.1046/j.1365-2133.2000.03287.x.CrossRefPubMed

33.

Meier F, et al. Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol. 2000;156(1):193–200. https://doi.org/10.1016/S0002-9440(10)64719-0.CrossRefPubMedPubMedCentral

34.

Zhang T, et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol. 2006;36(2):457–67. https://doi.org/10.1002/eji.200526208.CrossRefPubMed

35.

Vörsmann H, et al. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis. 2013;4(7):719–719. https://doi.org/10.1038/cddis.2013.249.CrossRef

36.

Leight JL, Tokuda EY, Jones CE, Lin AJ, Anseth KS. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Proc Natl Acad Sci U S A. 2015;112(17):5366–71. https://doi.org/10.1073/pnas.1505662112.CrossRefPubMedPubMedCentral

37.

Kaur G, Dufour JM. Cell lines: valuable tools or useless artifacts. Spermatogenesis. 2012;2(1):1–5. https://doi.org/10.4161/spmg.19885.CrossRefPubMedPubMedCentral

38.

Murekatete B, et al. Targeting insulin-like growth factor-I and extracellular matrix interactions in melanoma progression. Sci Rep. 2018;8(1):583. https://doi.org/10.1038/S41598-017-19073-4.CrossRefPubMedPubMedCentral

39.

Duan J, et al. 3D bioprinted GelMA/PEGDA hybrid scaffold for establishing in-vitro model of melanoma. J Microbiol Biotechnol. 2022;32(4):1–10. https://doi.org/10.4014/JMB.2111.11003.CrossRef

40.

Semlin L, Schäfer-Korting M, Borelli C, Korting HC. In vitro models for human skin disease. Drug Discov Today. 2011;16(3–4):132–9. https://doi.org/10.1016/j.drudis.2010.12.001.CrossRefPubMed

41.

Borchers AH, Steinbauer H, Schafer BS, Kramer M, Bowden GT, Fusenig NE. Fibroblast-directed expression and localization of 92-kDa type IV collagenase along the tumor-stroma interface in an in vitro three-dimensional model of human squamous cell carcinoma. Mol Carcinog. 1997;19(4):258–66. https://doi.org/10.1002/(SICI)1098-2744(199708)19:4%3c258::AID-MC7%3e3.0.CO;2-8.CrossRefPubMed

42.

Commandeur S, de Gruijl FR, Willemze R, Tensen CP, El Ghalbzouri A. An in vitro three-dimensional model of primary human cutaneous squamous cell carcinoma. Exp Dermatol. 2009;18(10):849–56. https://doi.org/10.1111/j.1600-0625.2009.00856.x.CrossRefPubMed

43.

Commandeur S, Van Drongelen V, De Gruijl FR, El Ghalbzouri A. Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma. Cancer Sci. 2012;103(12):2120–6. https://doi.org/10.1111/cas.12026.CrossRefPubMedPubMedCentral

44.

Brauchle E, Johannsen H, Nolan S, Thude S, Schenke-Layland K. Design and analysis of a squamous cell carcinoma in vitro model system. Biomaterials. 2013;34(30):7401–7. https://doi.org/10.1016/J.BIOMATERIALS.2013.06.016.CrossRefPubMed

45.

Bouez C, et al. The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Hum Cancer Biol. 2006;12(5):1463–9. https://doi.org/10.1158/1078-0432.CCR-05-1456.CrossRef

46.

Berning M, Prätzel-Wunder S, Bickenbach JR, Boukamp P. Three-dimensional in vitro skin and skin cancer models based on human fibroblast-derived matrix. Tissue Eng Part C Methods. 2015;21(9):958–70. https://doi.org/10.1089/ten.tec.2014.0698.CrossRefPubMed

47.

Linde N, Gutschalk CM, Hoffmann C, Yilmaz D, Mueller MM. Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. PLoS ONE. 2012;7(7): e40058. https://doi.org/10.1371/journal.pone.0040058.CrossRefPubMedPubMedCentral

48.

Kochanek SJ, Close DA, Johnston PA. High content screening characterization of head and neck squamous cell carcinoma multicellular tumor spheroid cultures generated in 384-well ultra-low attachment plates to screen for better cancer drug leads. Assay Drug Dev Technol. 2019;17(1):17–36. https://doi.org/10.1089/ADT.2018.896/ASSET/IMAGES/LARGE/FIGURE7.JPEG.CrossRefPubMedPubMedCentral

49.

Grando SA, Schofield OM, Skubitz AP, Kist DA, Zelickson BD, Zachary CB. Nodular basal cell carcinoma in vivo vs in vitro. Establishment of pure cell cultures, cytomorphologic characteristics, ultrastructure, immunophenotype, biosynthetic activities, and generation of antisera. Arch Dermatol. 1996;132(10):1185–93. https://doi.org/10.1001/archderm.132.10.1185.CrossRefPubMed

50.

Asada M, et al. Growth characteristics and differentiation of basal cell carcinoma in vitro–immunohistochemical, gel electrophoretic, and ultrastructural analysis. J Invest Dermatol. 1992;99(4):474–81. https://doi.org/10.1111/1523-1747.EP12616161.CrossRefPubMed

51.

Flaxman BA, Van Scott EJ. Keratinizationin vitro of cells from a basal cell carcinoma. JNCI J Natl Cancer Inst. 1968;40(2):411–22. https://doi.org/10.1093/jnci/40.2.411.CrossRefPubMed

52.

Hehlgans S, et al. “Radiation sensitization of basal cell and head and neck squamous cell carcinoma by the hedgehog pathway inhibitor vismodegib,” Int J Mol Sci. 2018;19:(9). https://doi.org/10.3390/IJMS19092485.

Titel: Human Skin Cancer: an Overview Of Animal, Ex Vivo, and In Vitro Models
verfasst von: Catalina Gaviria Agudelo
Luz Marina Restrepo
Publikationsdatum: 18.06.2022
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 3/2022
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-022-00361-w

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Human Skin Cancer: an Overview Of Animal, Ex Vivo, and In Vitro Models

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Dermatologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Neutrophilic Dermatosis and Management Strategies for the Inpatient Dermatologist

PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist

Psychological Considerations in Patients Undergoing Patch Testing

Cellulitis and Its Mimickers: an Approach to Diagnosis and Management

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Dermatologie